Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children

Basu, Kaninika, Nair, Arun, Williamson, Peter A, Mukhopadhyay, Somnath and Lipworth, Brian J (2009) Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children. Annals of Allergy, Asthma and Immunology, 103 (5). pp. 436-441. ISSN 1081-1206

Full text not available from this repository.

Abstract

BACKGROUND

Using cyclodextrin with budesonide enables it to be formulated in a solution for nebulization.

OBJECTIVE

To observe the effects of a Captisol-enabled budesonide solution (CBIS), 60 microg twice daily, delivered via a nebulizer (eFlow), compared with a conventional budesonide suspension (Pulmicort Respules), 250 microg twice daily, delivered via another nebulizer (LC Plus), using fraction of exhaled nitric oxide (FE(NO)) and overnight urinary cortisol to creatinine ratio as the primary outcomes for efficacy and systemic bioactivity.

METHODS

A randomized, open-label, crossover study was conducted in 12 children with mild-to-moderate persistent asthma (aged 5-12 years). Measurements were performed after a 2-week steroid washout at baseline and at the end of each 2-week randomized treatment.

RESULTS

The nebulization time was shorter (95% confidence interval [CI], 0.83-5.63 minutes; P = .03) with CBIS (mean, 1.77 minutes) than with Pulmicort Respules (mean, 5.01 minutes). The reduction in FE(NO) with CBIS from pooled baseline was 2.45-fold (95% CI, 1.87-3.21; P < .001); and with Pulmicort Respules, 3.18-fold (95% CI, 2.26-4.47; P < .001). No statistically significant changes from pooled baseline in lung function and overnight urinary cortisol to creatinine ratio were observed with either treatment.

CONCLUSIONS

The nebulization time was shorter with CBIS compared with Pulmicort Respules. Both formulations exhibited similar anti-inflammatory activity in terms of reducing FE(NO), with no detectable difference between them when used in a putative microgram nominal dose ratio of 1:4. Neither formulation produced significant adrenal suppression

Item Type: Article
Additional Information: Impact Factor: 2.833
Schools and Departments: Brighton and Sussex Medical School > Clinical Medicine
Subjects: R Medicine
Related URLs:
Depositing User: Patricia Butler
Date Deposited: 03 Dec 2012 13:15
Last Modified: 03 Dec 2012 13:15
URI: http://sro.sussex.ac.uk/id/eprint/43260
📧 Request an update